INHIBIKASE THERAPEUTIC

2.9200

29-November-24 12:45:00

15 minutes delayed

Stocks

+0.1900

+6.96%

Today's range

2.7600 - 2.9800

ISIN

N/A

Source

NASDAQ

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

04 Dec 2023 07:35:00 By Nasdaq GlobeNewswire
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

14 Nov 2023 15:30:06 By Nasdaq GlobeNewswire
Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

07 Nov 2023 08:28:32 By Nasdaq GlobeNewswire
Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023

07 Nov 2023 07:00:01 By Nasdaq GlobeNewswire
Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment

16 Oct 2023 06:00:27 By Nasdaq GlobeNewswire
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

04 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.